Gemcitabine & oxaliplatin

DRUG2 trials

Sponsors

3D Medicines (Sichuan) Co., Ltd., Massachusetts General Hospital

Conditions

B-cell LymphomasBiliary Tract NeoplasmsLarge B-cell LymphomaLymphomaRelapsed/Refractory Large B-cell Lymphoma

Phase 2

GLORY: Glofit-GemOx With Liso-Cel For Lymphoma

Not yet recruitingNCT07711483

Massachusetts General HospitalB-cell Lymphomas, Large B-cell Lymphoma, Lymphoma +1

Start: 2026-10-14End: 2030-10-01Target: 56Updated: 2026-07-17

Phase 3

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Active, not recruitingNCT03478488

3D Medicines (Sichuan) Co., Ltd.Biliary Tract Neoplasms

Start: 2018-04-16End: 2026-12-31Target: 480Updated: 2025-05-29

Related Papers

Envafolimab (KN035) plus gemcitabine and oxaliplatin (GEMOX) compared with GEMOX as first-line treatment for Chinese patients with advanced biliary tract cancer: A randomized, open-label, multi-center, phase III pivotal trial.

Journal of Clinical Oncology2026-05-28

Antibodies to watch in 2020.

2020-01-01328 citations